Početna stranica9VC • ETR
add
ATAI Life Sciences NV
Preth. zaklj. cijena
1,33 €
Godišnji raspon
0,93 € - 2,50 €
Tržišna kapitalizacija
293,70 mil. USD
Prosječna količina
1,55 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Prihod | −5,00 tis. | −127,78 % |
Operativni troškovi | 29,34 mil. | −12,62 % |
Neto dohodak | −38,96 mil. | −112,98 % |
Neto profitabilnost | 779,16 tis. | 866,72 % |
Zarada po dionici | −0,24 | −100,00 % |
EBITDA | −29,12 mil. | 12,97 % |
Efektivna porezna stopa | 1,81 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 62,33 mil. | −65,23 % |
Ukupna imovina | 159,39 mil. | −45,69 % |
Ukupne obveze | 42,83 mil. | −12,87 % |
Ukupni kapital | 116,55 mil. | — |
Dionice u optjecaju | 198,31 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,92 | — |
Povrat imovine | −41,11 % | — |
Povrat kapitala | −46,44 % | — |
Tok novca
Neto promjena novca
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −38,96 mil. | −112,98 % |
Gotovina od poslovanja | −24,30 mil. | −10,62 % |
Gotovina iz ulaganja | 6,56 mil. | 897,08 % |
Gotovina iz financiranja | 154,00 tis. | 101,82 % |
Neto promjena novca | −17,46 mil. | 44,50 % |
Slobodan tok novca | −1,72 mil. | 86,74 % |
Više
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Glavni izvršni direktor
Osnovano
2018
Web-lokacija
Zaposlenici
54
